Aktienanalyse zu Verastem Inc (VSTM)VSTMVerastem Inc

Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Verastem Inc (VSTM) appears to be a good buy right now due to its recent positive developments, including a 4.79% increase over the last five days and a significant projected revenue increase of 981.8% year-over-year. The stock is currently priced at $7.22, which is below the analyst price targets of $12 and $13, indicating potential upside. However, the main risk is the company's ongoing losses, with a net income of -34,673,000 USD in Q2 2026, which investors should monitor closely.

5 analysts cover VSTM: 4 rate it Buy, 1 Hold and 0 Sell. The average price target is 15.60.